## A-Engrossed House Bill 2955

Ordered by the House April 7 Including House Amendments dated April 7

Sponsored by Representative TRAN; Representative JAVADI (Presession filed.)

## SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure. The statement includes a measure digest written in compliance with applicable readability standards.

Digest: The Act requires the state Medicaid program to cover a type of diabetes treatment in some cases. (Flesch Readability Score: 60.1).

Requires medical assistance to include continuous glucose monitors for specified recipients of medical assistance.

Declares an emergency, effective on passage.

1	A BILL FOR AN ACT
2	Relating to continuous glucose monitors; and declaring an emergency.
3	Be It Enacted by the People of the State of Oregon:
4	SECTION 1. Section 2 of this 2025 Act is added to and made a part of ORS chapter 414.
5	SECTION 2. (1) As used in this section, "continuous glucose monitor" means:
6	(a) An instrument or device that is designed and offered for the purpose of measuring
7	glucose levels at set intervals; and
8	(b) Any repair or replacement parts for the instrument or device.
9	(2) Notwithstanding ORS 414.065 and 414.690, medical assistance shall include a contin-
10	uous glucose monitor prescribed for a recipient of medical assistance if the recipient:
11	(a)(A) Is diagnosed with any type of diabetes by the recipient's primary care physician
12	or another licensed health care provider whose authorized scope of practice includes the di-
13	agnosis of diabetes and:
14	(i) Is treated with insulin; or
15	(ii) Has a history of severe hypoglycemia; or
16	(B) Is diagnosed with gestational diabetes by the recipient's primary care physician or
17	another licensed health care provider whose authorized scope of practice includes the diag-
18	nosis of gestational diabetes; and
19	(b) Attends a visit with a health care provider to assess the efficacy of using the con-
20	tinuous glucose monitor to treat the recipient's diabetes:
21	(A) At least once every six months during the first 18 months after receiving a pre-
22	scription for the continuous glucose monitor; and
23	(B) At least once every 12 months after the initial 18-month period.
24	SECTION 3. Section 2 of this 2025 Act becomes operative on January 1, 2026.
25	SECTION 4. The Oregon Health Authority may take any action, including seeking any
26	federal approval necessary to implement the provisions of section 2 of this 2025 Act, before

## A-Eng. HB 2955

the operative date specified in section 3 of this 2025 Act that is necessary to enable the authority to exercise, on and after the operative date specified in section 3 of this 2025 Act, all of the duties, functions and powers conferred on the authority by section 2 of this 2025 Act.

4 <u>SECTION 5.</u> Section 2 of this 2025 Act applies to prescriptions issued on or after the op-5 erative date specified in section 3 of this 2025 Act.

6 <u>SECTION 6.</u> This 2025 Act being necessary for the immediate preservation of the public 7 peace, health and safety, an emergency is declared to exist, and this 2025 Act takes effect 8 on its passage.

9